Pappas Capital

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating disease-driving cells. Utilizing its unique cytotoxicity-targeting chimera platform, the company focuses on creating oncology therapeutics that address not only cancer but also inflammatory and autoimmune diseases. By targeting and eliminating these harmful cells, Solu Therapeutics seeks to enhance treatment efficacy and reduce the associated risks in oncology, ultimately aiming to improve patient outcomes in various medical conditions.

Enlaza Therapeutics is a biotechnology research company founded in 2020 and headquartered in La Jolla, California. The company focuses on developing novel protein therapeutics aimed at providing more effective and safer treatment options for patients. Utilizing advanced synthetic biology technology, Enlaza Therapeutics specializes in site-specific covalent coupling driven by drug binding. This innovative approach allows the development of first-in-class covalent biologics that have the potential to deliver enhanced efficacy and improved safety profiles compared to traditional therapies.

RoboCT Technology is a developer of advanced exoskeleton robot technology aimed at assisting patients with lower-body motor dysfunction in regaining their ability to walk. The company specializes in creating rehabilitation equipment and intelligent solutions for medical institutions as well as individual users, focusing on the rehabilitation and elderly care sectors. By integrating human-computer interaction, artificial intelligence, data analysis, and cloud computing, RoboCT seeks to enhance human mobility and overall bodily function through innovative robotic solutions. The company is not only dedicated to improving rehabilitation outcomes but also aims to expand the application of its exoskeleton technology across various fields, including health, industry, transportation, security, and entertainment.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

VFlow Tech is a Singapore-based company specializing in the manufacturing of modular vanadium redox flow batteries. It focuses on providing energy storage solutions that cater to the utility and renewable energy sectors. VFlow Tech employs its unique intellectual property to create long-lasting, high-performing, and cost-effective flow batteries suitable for large-scale energy storage applications, ranging from households and micro-grids to grid-level systems. The company's innovative modular design allows for scalability, while its emphasis on industry-focused research ensures that the products are reliable and meet user needs. With in-house expertise in renewable energy technologies, VFlow Tech delivers comprehensive energy and storage solutions, characterized by stable performance, environmental friendliness, and minimal degradation over time.

Aktis Oncology is a biotechnology company focused on the discovery and development of a new class of targeted radiopharmaceuticals aimed at treating various solid tumor cancers. The company has developed proprietary platforms to create tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered for high tumor penetration and prolonged residence time, allowing for effective tumor elimination while reducing the side effects typically associated with cancer treatments. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing treatment precision and efficacy.

NuProbe, Inc. is a genomics and molecular diagnostics company that specializes in noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative polymerase chain reaction (qPCR) mutation detection. The company's innovative probe technology facilitates a Sample-In Answer-Out (SIAO) solution, integrating cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations. This precision diagnostic technology is designed for the early detection of cancer and infectious diseases, offering high sensitivity and the ability to capture disease signatures comprehensively. As a result, healthcare specialists are empowered to act swiftly, enabling timely treatment for patients.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Horizon Quantum Computing Pte. Ltd., established in 2018 and headquartered in Singapore, focuses on creating software development tools that facilitate the development of quantum software applications. The company's innovative tools aim to bridge the gap between quantum computing and conventional software development, allowing researchers to enhance their productivity. By utilizing abstraction techniques, Horizon's solutions enable software engineers to engage in quantum application development without requiring prior experience in quantum computing. This approach not only simplifies the development process but also broadens access to quantum-enhanced applications, contributing to advancements in the field of quantum technology.

Us2.ai is a Singapore-based company that specializes in developing software and digital tools for echocardiography using artificial intelligence. The company's platform automates the manual process of measuring and interpreting echocardiograms, which are ultrasound images of the heart. This automation provides decision support tools designed to save doctors time, improve clinical trials for pharmaceutical companies, and enhance the detection of hard-to-diagnose cardiovascular conditions in hospitals. Us2.ai aims to simplify access to results of echo analysis and heart ultrasound through its online solutions.

Plexium, Inc. is a biotechnology company based in San Diego, California, specializing in the development of targeted protein degradation therapeutics aimed at treating cancer and neurodegenerative diseases. Founded in 2017, Plexium focuses on identifying E3 ligase modulating small molecules to create innovative therapies. The company has developed a screening platform known as DELPhe, which utilizes advanced techniques to miniaturize cell-based assays for high-content readouts. This platform enables the modulation of E3 ligases to selectively target various cancers, including small cell lung and breast tumors, while also inducing immune responses. By exploring next-generation drug candidates that extend beyond traditional approaches, Plexium is poised to uncover new therapeutic possibilities across a wide range of medical applications.

AvengeBio is a biotechnology company based in Cambridge, Massachusetts, focused on developing cell-generated immunotherapies aimed at eradicating solid tumors. Founded in 2019, the company is advancing a drug delivery platform designed to enable the precision delivery of cytokines and other potent immunomodulatory molecules. This innovative approach allows for controlled release over time, fostering robust local and systemic anti-tumor immune responses while minimizing the toxicities typically associated with conventional immunotherapies. Through its research and development efforts, AvengeBio seeks to address the challenges posed by intractable solid tumors and improve treatment outcomes for cancer patients.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company leverages soluble guanylate cyclase (sGC) pharmacology to create next-generation sGC stimulators. Its pipeline includes Olinciguat, an orally administered vascular sGC stimulator in Phase II studies for sickle cell disease; Praliciguat, another oral sGC stimulator in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, a CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is exploring liver-targeted and lung-targeted sGC stimulators. The company was incorporated in 2018.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Allievex Corporation is a clinical-stage biotechnology company based in Marblehead, Massachusetts, focused on developing and commercializing innovative, non-opioid therapeutics for rare pediatric neurodegenerative diseases. Founded in 2018, the company is primarily known for its investigational enzyme replacement therapy, tralesinidase alfa. This therapy combines recombinant human alpha-N-acetyglucosaminidase with a peptide derived from insulin-like growth factor 2, aiming to provide treatment options for children affected by Sanfilippo syndrome type B and mucopolysaccharidosis IIIB. Through its targeted approach, Allievex seeks to address the unmet medical needs of patients with these rare and debilitating conditions.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for debilitating liver diseases. Founded in 2018 and headquartered in Foster City, California, Mirum's lead product candidate is maralixibat, an investigational oral drug currently in Phase 3 clinical trials targeting progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. The company’s approved product, Livmarli, is aimed at alleviating cholestatic pruritus in patients with Alagille syndrome. In addition to maralixibat, Mirum is also advancing the development of volixibat, which is intended for treating intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Through its focused pipeline, Mirum aims to address significant unmet medical needs in rare and orphan liver diseases.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

OrphoMed, Inc. is a San Francisco-based pharmaceutical company that specializes in developing novel therapies for conditions such as irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis. Established in 2015, the company utilizes its proprietary DIMERx™ platform technology to create first-in-class therapeutic dimer conjugates aimed at addressing visceral hypersensitivity and pancreatitis. Among its key pipeline candidates is ORP-101, a peripherally acting sodium ion channel blocker that acts as a μ agonist and κ antagonist, designed to minimize abuse potential and reduce risks associated with pancreatitis. OrphoMed is also working on ORP-105, a non-addictive, centrally-acting analgesic, and ORP-110, a potentiator for cystic fibrosis treatment. The company's innovative approach not only aims to reshape pain management but also seeks to fulfill unmet medical needs across various gastrointestinal and pain-related disorders, leveraging the safety and efficacy of its compounds, which have proven track records for other indications.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. It specializes in the design and development of multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's innovative synthetic chemistry platform enables the production of next-generation fungicides, including BAG8, a multisite fungicide, and BN2266, which targets mRNA processing. The company is also developing a dual function nematicide-fungicide for root protection and endo-parasiticides that can overcome resistance. By leveraging the unique properties of boron, Boragen aims to create sustainable agricultural solutions that reduce the probability of fungicide resistance and minimize chemical usage while maintaining efficacy across various sectors.

Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

Balance Therapeutics is a research and development company based in San Bruno, California, with a subsidiary in Melbourne, Australia. Founded in 2009, the company focuses on developing pharmacological therapeutics to address intellectual disability conditions, particularly Down syndrome and Alzheimer’s disease. Their lead product, BTD-001 DS102, is an orally administered molecule currently undergoing clinical trials for treating young adults and adolescents with Down syndrome. The company's approach, licensed from Stanford University, has shown promising results in addressing cognitive deficits in animal models of these conditions.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Lumena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for rare liver diseases, particularly cholestatic liver disease. Its lead candidate, LUM001, targets a specific transporter in the intestine, which reduces the risk of systemic toxicities by being minimally absorbed in the body. LUM001 has been extensively studied across 12 clinical trials involving over 1,400 subjects, positioning it for rapid advancement in both pediatric and adult patients. While Lumena's primary objective is to provide novel treatments for rare liver diseases, its therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which are increasingly recognized as significant health concerns in both children and adults.

Envisia Therapeutics Inc. is a company focused on discovering and developing innovative therapies for ophthalmic medical needs. Founded in 2013 and based in Durham, North Carolina, the company utilizes its proprietary Particle Replication In Non-Wetting Templates (PRINT) technology to create a range of particle-based therapies. Envisia is particularly known for its lead product, ENV515, a prostaglandin analogue designed to deliver sustained intraocular pressure reduction for extended periods. In addition to this, the company is developing glaucoma drug therapies that leverage PRINT particle therapeutics to improve drug delivery and efficacy while addressing common barriers faced by existing ocular treatments. As the demand for more effective ocular therapeutics continues to grow, Envisia aims to enhance patient outcomes and convenience in the management of ocular diseases.

Lumena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for rare liver diseases, particularly cholestatic liver disease. Its lead candidate, LUM001, targets a specific transporter in the intestine, which reduces the risk of systemic toxicities by being minimally absorbed in the body. LUM001 has been extensively studied across 12 clinical trials involving over 1,400 subjects, positioning it for rapid advancement in both pediatric and adult patients. While Lumena's primary objective is to provide novel treatments for rare liver diseases, its therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which are increasingly recognized as significant health concerns in both children and adults.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that specializes in developing therapeutics for rare and ultra-rare diseases, particularly serious genetic disorders. The company focuses on identifying and commercializing innovative treatments that address significant unmet medical needs. Its product portfolio includes Crysvita, which is used to treat X-linked hypophosphatemia, and Mepsevii, indicated for Mucopolysaccharidosis VII. By leveraging existing scientific knowledge and emphasizing clear mechanisms of action, Ultragenyx aims to create impactful therapies for conditions that currently lack effective treatments. The company prioritizes efficient development strategies in a field characterized by limited information and established precedents, drawing on the management team's expertise to advance its mission of improving patient outcomes in rare disease populations.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

IlluminOss Medical, Inc., established in 2007 and headquartered in East Providence, Rhode Island, is a medical device company specializing in orthopedic fracture repair. It designs, develops, and markets products based on its proprietary IlluminOss System, which employs a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants for bone stabilization. This minimally invasive technology is particularly suited for treating osteoporotic and compromised bone. The company's products are CE-marked and FDA-cleared for various anatomical sites and are distributed in several European countries.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that specializes in developing therapeutics for rare and ultra-rare diseases, particularly serious genetic disorders. The company focuses on identifying and commercializing innovative treatments that address significant unmet medical needs. Its product portfolio includes Crysvita, which is used to treat X-linked hypophosphatemia, and Mepsevii, indicated for Mucopolysaccharidosis VII. By leveraging existing scientific knowledge and emphasizing clear mechanisms of action, Ultragenyx aims to create impactful therapies for conditions that currently lack effective treatments. The company prioritizes efficient development strategies in a field characterized by limited information and established precedents, drawing on the management team's expertise to advance its mission of improving patient outcomes in rare disease populations.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

TyRx is a company specializing in the design, development, and commercialization of resorbable polymeric biomaterials for medical applications. Based in Monmouth Junction, New Jersey, TyRx was founded in 1997. The company offers two primary products: PIVIT CRM, a mesh-based pouch containing antibacterial agents to protect against microbial colonization during and after the surgical implant of generators or defibrillators; and AIGISRx Flat, an antibacterial product designed to prevent infections related to implanted pacemakers and defibrillators.

Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Blue Bell, Pennsylvania, specializing in the discovery, development, and commercialization of small molecule drug therapies targeting immune system disorders. Its lead candidate, ACH-4471, is a factor D inhibitor currently undergoing Phase II clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. The company is also advancing other factor D inhibitors, including ACH-5228 and ACH-5548, both of which are in Phase I clinical trials for PNH and other complement-mediated diseases. Achillion has established license agreements with Ora, Inc. for the development of ACH-702 and with GCA Therapeutics, Ltd. for elvucitabine, a treatment for hepatitis B and HIV. Founded in 1998, Achillion operates as a subsidiary of Alexion Pharmaceuticals, Inc. Its focus is on advancing therapies that address disorders linked to the complement system, which plays a crucial role in the innate immune response.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.

BaroSense is focused on developing and commercializing innovative medical devices aimed at addressing obesity, a significant healthcare challenge in the United States. The company aims to provide safe, simple, and effective alternatives to surgical treatments for obesity, catering to individuals who require assistance beyond traditional dieting methods and wish to avoid extensive and irreversible surgical options. BaroSense's product offerings include minimally invasive therapeutic procedures and devices, such as a trans-oral endoscopic restrictive implant system, designed to facilitate weight loss in a less invasive manner.

Biosyntech is a Canadian biotechnology company based in Laval, incorporated in 1994. It specializes in developing biotherapeutic thermogels for tissue repair and therapeutic agent delivery. The company's technology platform, BST-Gel, utilizes chitosan, a natural biopolymer derived from crustacean shells, to create hydrogels. Biosyntech's lead products include BST-CarGel for cartilage repair, BST-DermOn for wound healing, and BST-InPod for treating chronic pain due to plantar fat pad atrophy in the heel and forefoot. The company has collaborated with Nicholas Piramal India Ltd. on clinical studies for BST-InPod. Additionally, Biosyntech develops products like BST-Ossifil, BST-Ossifix, and BST-Disc for bone repair and intervertebral disc restoration.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for serious diseases, particularly those associated with inflammation, including cardiovascular and autoimmune conditions. Founded in 2004 and headquartered in Hayward, California, the company is advancing several product candidates. Its notable projects include Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for exocrine pancreatic insufficiency, and Blisibimod, which is undergoing Phase II trials for B-cell mediated autoimmune diseases such as IgA nephropathy. Anthera also develops varespladib methyl and varespladib sodium, both of which are in various stages of clinical trials for acute coronary syndrome and sickle cell disease, respectively. The company has established license agreements with major pharmaceutical firms, including Amgen and Eli Lilly, to enhance its development and commercialization efforts.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule IND candidates against clinically validated therapeutic targets, focused primarily on the treatment of Cancer and infectious diseases.

Optherion, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2005. The company specializes in the development of diagnostic tools and disease-modifying therapeutics aimed at managing and treating early-stage age-related macular degeneration, dense deposit disease, atypical hemolytic uremic syndrome, and other chronic diseases related to the alternative complement cascade. Through its innovative approaches, Optherion seeks to address significant medical needs in the field of ophthalmology and related disorders.

FlowCardia, Inc. is a medical device company established in 2002 that specializes in developing innovative catheter-based technologies aimed at facilitating guidewire crossing of chronic total occlusions (CTOs) in both coronary and peripheral arteries. CTOs pose significant challenges in interventional therapy, often leading to patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia is dedicated to addressing this critical need within the medical community by providing advanced solutions that enhance the safety and efficacy of CTO recanalization.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

Gentis is a developer of biomaterials-based products focused on addressing early-stage degeneration of the spine. Founded in 2000 and headquartered in Wayne, Pennsylvania, the company offers a patented product called DiscCell. This innovative injectable material is designed to augment or replace the diseased nucleus pulposus of the spinal disc. DiscCell is characterized by its in-situ setting, radio-opacity, and non-hydrogel polymer composition, which collectively aim to alleviate back or leg pain and prevent recurrence at the treatment site.

Cequent Pharmaceuticals is an early-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA interference (RNAi) therapies to prevent and treat various human diseases, including inflammatory conditions and cancer. Founded in 2006, Cequent is pioneering innovative therapeutics utilizing its proprietary TransKingdom RNA interference (tkRNAi) technology, which safely and effectively deactivates specific disease-causing genes. This technology employs non-pathogenic bacteria to produce and deliver RNAi directly into cells. Currently, Cequent's leading drug candidates are in pre-clinical development, specifically targeting colon cancer prevention and inflammatory bowel disease. The company's scientific foundation is rooted in significant research conducted at the Institut Pasteur in Paris and the Beth Israel Deaconess Medical Center/Harvard Medical School.

Athersys, Inc. is a biotechnology company headquartered in Cleveland, Ohio, specializing in regenerative medicine. The company focuses on the research and development of therapeutic products aimed at treating various disease indications, including neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary issues. Its primary product, MultiStem cell therapy, is an allogeneic stem cell treatment currently undergoing Phase III clinical trials for ischemic stroke and Phase II trials for acute myocardial infarction. Additionally, MultiStem has completed Phase I trials concerning certain blood-borne cancers. Athersys is also dedicated to developing therapies for veterinary applications and has established collaboration agreements with Healios K.K. and the University of Minnesota to further advance its MultiStem platform in several disease contexts. The company has engaged in various revenue-generating activities, including corporate collaborations, licensing agreements, and government grants. Founded in 1995, Athersys is committed to addressing unmet medical needs through innovative biopharmaceuticals.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for serious diseases, particularly those associated with inflammation, including cardiovascular and autoimmune conditions. Founded in 2004 and headquartered in Hayward, California, the company is advancing several product candidates. Its notable projects include Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for exocrine pancreatic insufficiency, and Blisibimod, which is undergoing Phase II trials for B-cell mediated autoimmune diseases such as IgA nephropathy. Anthera also develops varespladib methyl and varespladib sodium, both of which are in various stages of clinical trials for acute coronary syndrome and sickle cell disease, respectively. The company has established license agreements with major pharmaceutical firms, including Amgen and Eli Lilly, to enhance its development and commercialization efforts.

LipoScience is a Raleigh, North Carolina-based company specializing in personalized diagnostics through the use of nuclear magnetic resonance (NMR) technology. The company has developed the NMR LipoProfile test, its flagship diagnostic tool, which quantitatively measures low density lipoprotein particles (LDL-P) in blood samples. This test provides physicians and patients with critical information to tailor heart disease risk management effectively. Since its inception, LipoScience has seen significant adoption, with over 8 million NMR LipoProfile tests ordered to date.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Spherics develops proprietary bioadhesive encapsulation technologies to improve the oral absorption of small molecule drugs.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

NuVasive, Inc. is a medical device company that specializes in developing and marketing minimally disruptive surgical products and integrated solutions for spine surgery. Founded in 1997 and headquartered in San Diego, California, the company focuses on enhancing surgical outcomes through its portfolio, which includes surgical access instruments, spinal implants, fixation systems, and biologics. Key products feature the Maximum Access Surgery platform, which incorporates advanced nerve detection and intraoperative monitoring services. NuVasive also offers a range of specialized implants, including cellular bone matrices and synthetic bone substitutes, aimed at facilitating restorative and fusion procedures for both thoracolumbar and cervical spine applications. Additionally, the company provides innovative systems, such as the Integrated Global Alignment platform and magnetically adjustable implant systems, and serves a diverse clientele including patients, surgeons, hospitals, and insurers through various sales channels.

LiveWire Logic provides AI technologies that can conduct human-like conversations to help customers make purchase decisions. It was founded in 2000 and is based in Morrisville, North Carolina.

VFlow Tech is a Singapore-based company specializing in the manufacturing of modular vanadium redox flow batteries. It focuses on providing energy storage solutions that cater to the utility and renewable energy sectors. VFlow Tech employs its unique intellectual property to create long-lasting, high-performing, and cost-effective flow batteries suitable for large-scale energy storage applications, ranging from households and micro-grids to grid-level systems. The company's innovative modular design allows for scalability, while its emphasis on industry-focused research ensures that the products are reliable and meet user needs. With in-house expertise in renewable energy technologies, VFlow Tech delivers comprehensive energy and storage solutions, characterized by stable performance, environmental friendliness, and minimal degradation over time.